| abstract |
The present invention provides nanotransporters and delivery complexes for use in delivery of nucleic acid molecules and/or other pharmaceutical agents in vivo and in vitro. In addition, the invention features chemically-modified RNA silencing agents (e.g., siRNAs) that are stable in vivo and silence target RNA that is associated with a metabolic disorder, as well as delivery complexes comprising said RNA silencing agents in association with the nanotransporters of the invention. The featured RNA silencing agents and delivery complexes are effective therapeutics for targeting disease genes, e.g., genes involved in metabolic disorders. |